Archive
Decommissioning of the research reactor Proteus
Start of the public examination period for decommissioning of the nuclear facility Proteus at the Paul Scherrer Institute PSIThe nuclear research facility Proteus is a so-called zero-power reactor. In service, the thermal output of the reactor was limited to a maximum of 1 kW. That means this is an experimental reactor that was run at a power level so low that it did not require cooling. Proteus went into service in 1968. The PSI would like to decommission the facility. The decommissioning project is now being publicly announced in the legally prescribed, official publications.
Developing a new drug against thyroid cancer
Researchers at the Paul Scherrer Institute PSI have developed a drug to trace and treat a particularly malignant strain of thyroid cancer more effectively. One advantage of the new drug is that it can be used to treat a strain of thyroid cancer where the established treatment is ineffective. The researchers at PSI have developed the new drug to such an extent that an initial study conducted on cancer patients at the University Hospital Basel can now get underway.
A micrometer-sized model of the Matterhorn
Researchers at the Paul Scherrer Institute have produced large numbers of detailed models of the Matterhorn, each one less than a tenth of a millimetre in size. With this, they demonstrated how 3-D objects so delicate could be mass-produced. Materials whose surface is covered with a pattern of such tiny 3-D structures often have special properties, which could for example help to reduce the wear and tear of machine parts.
The hotlab research facility
Start of the public examination period for renewed authorization to operate the research facility hotlab at the Paul Scherrer Institute PSIThe hotlab at the Paul Scherrer Institute PSI is a facility, unique in Switzerland, where researchers study highly radioactive materials in specially shielded chambers called hot cells. It serves the needs of applied materials research on highly radioactive samples from core structural components and fuel rods from nuclear power plants, research reactors, and the PSI radiation facilities. Through its operation of the hotlab, the Paul Scherrer Institute also contributes to the safety of the nuclear power plants in Switzerland. Around thirty staff members attend to the hotlab's safety technology and analysis infrastructure.
Probing what sets the heart racing
New insights into the workings of important drug receptorsMany medical drugs operate on specific receptors located in the outer walls of our body’s cells. One of these is called the beta-1 adrenergic receptor. Among other things, it is responsible for palpitation, the racing pulse that we feel with stage fright or infatuation. How it transmits signals to the cellular interior can now be revealed in detail. These findings could help scientists better understand many drugs' mode of action.
At the interface
Interview with Stefan Janssen, Head of the User OfficeStefan Janssen is Head of the User Office at Paul Scherrer Institute PSI. In an interview, he explains why the PSI’s large research facilities are popular with researchers coming from other institutions, how he handles the many applications and how he supports users who come here to conduct experiments.
Slowed down current could point the way to energy-saving computers
Computers and other electronic devices account for a substantial portion of worldwide energy use. With today’s technologies, it is not possible to reduce this energy consumption significantly any further; chips in the energy-saving electronics of the future will hence have to be made from novel materials. Researchers at the Paul Scherrer Institute PSI have now found important clues in the search for such materials.
Reappointment of the Directors of PSI and WSL
On application of the ETH Board, the Federal Council reappointed the Director of the Paul Scherrer Institute PSI, Joël Mesot, and the Director of the Swiss Federal Institute for Forest, Snow and Landscape Research WSL, Konrad Steffen, for another four years on 20 January 2016. Joël Mesot’s third term of office will start on 1 August 2016, Konrad Steffen’s second term of office on 1 July 2016.
Targeting cancer
There are tumours where nothing seems to help: not chemotherapy, not external radiation therapy, not an operation. Often, they have already metastasised and can no longer be destroyed using conventional methods. The only option left here is internal radiotherapy with targeted radioactive drugs that strike directly at the heart of the disease. In order to make this possible, twenty specialists have been conducting research at the Centre for Radiopharmaceutical Sciences at the Paul Scherrer Institute PSI, a joint facility of PSI, ETH Zurich and the University Hospital Zurich.
Neutrons reveal distribution of flux-tube islands
Usually, superconductors expel magnetic fields. In type II superconductors, however, thin channels – so-called flux tubes – are formed. The magnetic field is guided through these tubes while the rest of the material remains field-free and superconducting. In the metal niobium, the flux tubes bunch together into small islands that create complex patterns similar to those found in other fields of nature. A team of researchers from PSI and TU München were the first to conduct neutron experiments to study these patterns in niobium and determine the distribution of the islands in detail.